SIONNA THERAPEUTICS INC
SIONNASDAQ🏆 #3661 by market capEarnings Nov 11US Equity
$4.01▼ $0.03 (−0.74%)
Market closed · at closeTrack SION
Get earnings, price moves & breaking news on Telegram
24h▼ 0.7%
7d▲ 11.5%
14d▲ 2.6%
30d▼ 23.6%
ytd▼ 90.3%
1y▼ 89.4%
🏦Market Cap
$181M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $3.98 – $4.16
- 52-Week Range
- $3.55 – $54.97
- Volume (shares)
- 34,506
- Avg Volume (shares)
- —
- Shares Outstanding
- 45.2M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.17
- Dividend Yield
- —
- Dilution (1yr)
- −9.4%
SIONNA THERAPEUTICS INC
SIONFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$89M▲ +26.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$67M▲ +26.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.0M▼ −9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50M▲ +$22M YoY
StockOtter · stockotter.spaceAbout SIONNA THERAPEUTICS INC
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Hold
17 analysts
Strong Buy2
Buy4
Hold11
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.